You are here:Home Home>>News&Events>Highlights>


CanSino Biotechnology Successfully Passed EU GMP Audit

On February 3-4, 2015, a team led by the Qualified Person (QP) of 

an EU pharmaceutical enterprise conducted a two-day GMP audit of

CanSino Biotechnology Inc. This GMP audit was mainly for quality 

management systems, production equipment and facilities used in 

the production of human vaccines and biological products.CanSino

Biotechnology successfully passed this audit. Through this QP audit, 

it marks that CanSino has reached a significant milestone in the 

establishment of quality systems and maintaining high quality standards 

in the development and manufacturing of vaccine and biological products. 

It is also a key step in the transition from product development to product